E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
HIV and Hepatitis B infections |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10020161 |
E.1.2 | Term | HIV infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10019731 |
E.1.2 | Term | Hepatitis B |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary Objective: (i) Assessment of the feasibility of switching TDF to TAF in chronic HBV/HIV co-infected patients a. Assess recruitment rates b. Assess tolerability of switching TDF to TAF (ii) Assessment of the safety of switching TDF to TAF
|
|
E.2.2 | Secondary objectives of the trial |
Secondary Objective(s): to provide preliminary evidence of efficacy for a larger randomised trial, with the purpose of: (i) Choosing the optimal primary outcome, and (ii) Estimating the parameters for sample size calculation.
(a) The development of detectable HIV viraemia (HIV viral load ≥ 40 copies/ml) (b) The development of detectable HBV viraemia (≥ 20IU/ml) (c) the impact on renal markers (eGFR and creatinine clearance) at 48 weeks (d) the impact on liver inflammation (change in ALT >2x baseline at any point during 48 weeks) (e) the impact on lipid levels (change in total cholesterol at 48 weeks) (f) the impact on serological markers of HBV (e-Antigen and surface antigen loss at 48 weeks) (g) impact on bone health (change in bone mineral density at 48 weeks)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Hepatitis B surface antigen positive •HIV positive •Established on stable antiretroviral therapy regimen containing daily TDF for over 12 months •Hepatitis B DNA <20 IU/mL for over 12 months •HIV viral load <40 copies/ml for over 12 months
|
|
E.4 | Principal exclusion criteria |
•Age <18 or >75 years •eGFR < 30 mL/min •Evidence of disseminated malignancy •Women of child bearing potential not on approved effective contraception or practicing abstinence Effective protocol specified methods of birth control in this study are: - a combination of one hormonal method and one barrier method; - two barrier methods where one method is the male condom; - use of an intrauterine device (IUD) or tubal sterilisation; - true abstinence: when this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods),declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception].
•Previously in receipt of TAF •Concomitant use of medicinal products containing lamivudine or adefovir dipivoxil used for the treatment of HBV infection •TAF is transported by P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Medicinal products that strongly affect P-gp activity and BCRP may lead to changes in TAF absorption. Patients with concomitant use of medicinal products that induce P-gp activity e.g., rifampicin, rifabutin will be excluded. •Previous documentation of K65R mutation on HIV resistance testing •Known hypersensitivity to TAF, its metabolites or to any of the excipients listed in the Summary of Product Characteristics
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
i) Assessment of the feasibility and tolerability of switching TDF to TAF: • consent rate (of all patients screened) • recruitment rate (of all patients consented) (ii) Assessment of the safety of switching TDF to TAF: • The development of any Serious Adverse Event (SAE), Serious Adverse Reaction (SAR) or Unexpected Serious Adverse Reaction (USAR) that is not pre-specified or is a known consequence of disease progression
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Week 48 Interim analysis at 24 |
|
E.5.2 | Secondary end point(s) |
The secondary objectives of the study are to provide preliminary evidence of efficacy for a potential larger randomised trial, with the purpose of:
(i) Choosing the optimal primary outcome (ii) Estimating the parameters for sample size calculation.
(a) The development of detectable HIV viraemia (HIV viral load ≥ 40 copies/ml) (b) The development of detectable HBV viraemia (≥ 20IU/ml) (c) the impact on renal markers (eGFR and creatinine clearance) at 48 weeks (d) the impact on liver inflammation (change in ALT at 48 weeks) (e) the impact on lipid levels (change in total cholesterol at 48 weeks) (f) the impact on serological markers of HBV (e-Antigen and surface antigen loss at 48 weeks) (g) impact on bone health (change in bone mineral density at 48 weeks) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Week 48 Interim analysis at week 24 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 31 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 31 |